Sanofi Press Release: AMETHIST Trial Discontinued
We regret to inform you that in Sanofi’s quarterly press release issued today that the AMETHIST study has been discontinued….
We regret to inform you that in Sanofi’s quarterly press release issued today that the AMETHIST study has been discontinued….
Our summary of impact in 2023 is now available to read. After some time reflecting, everyone at Cure GM1 is proud…
Cure GM1, a 501(c)(3) nonprofit organization located in Albany, CA, USA is proud to announce a unique collaboration with xCures…
TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR) grant ($461,701) from the National…
Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood spot samples to the Gelb…
Our summary of impact in 2022 is now available to read. After some time reflecting, everyone at Cure GM1 is…
You can now download and read the touching and impactful summary of input from GM1 gangliosidosis caregivers and family given…
The GM1 Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) was held on Friday, October 14 as part of our 2022 virtual…
Our Caregiver Preferences study, The caregivers’ assessments of symptom impact and most important symptoms to treat, has been published in the…
TEGA Cure GM1 Collaboration PDF TEGA WORLD Pres 2023